Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Liver Neoplasms 1Head and Neck Neoplasms 1Fibrosis 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Enkephalin, Methionine × Clear all
NCT00783172 2018-09-06

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

Milton S. Hershey Medical Center

Phase 1 Terminated
4 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00255333 2007-05-14

INNO-105 in Patients With Solid Tumors

Innovive Pharmaceuticals

Phase 1 Terminated
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡